Withaferin A suppressed hepatocellular carcinoma progression through inducing IGF2BP3/FOXO1/JAK2/STAT3...

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Hepatocellular carcinoma (HCC) remains a significant global health challenge.
• Understanding the molecular mechanisms of anti-cancer agents is crucial for developing effective treatments.
• Withaferin A (WA) is a natural compound with demonstrated anti-cancer properties.

Purpose of the Study:

• To elucidate the molecular mechanisms by which Withaferin A (WA) exerts its anti-cancer effects in hepatocellular carcinoma (HCC).
• To investigate the role of insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) in WA-mediated HCC suppression.
• To identify key signaling pathways, including JAK2/STAT3 and FOXO1, involved in WA's action.

Main Methods:

• Gene and protein expression analysis using RT-qPCR and Western blot.
• Cell proliferation assays (CCK-8) and cell migration assays (Transwell).
• Investigation of reactive oxygen species (ROS) levels and signaling pathway modulation.

Main Results:

• WA significantly suppressed HCC cell proliferation and migration.
• WA inhibited the expression of IGF2BP3, which was found to promote HCC growth and migration by suppressing ROS.
• IGF2BP3 regulated FOXO1 expression, and its interaction with the JAK2/STAT3 signaling pathway and ROS production was elucidated, forming a feedback loop.

Conclusions:

• WA-induced ROS accumulation inhibits HCC progression by downregulating IGF2BP3 and subsequently deactivating the JAK2/STAT3 signaling pathway.
• Increased FOXO1 expression, driven by WA, further enhances ROS production and inhibits JAK2/STAT3 signaling, creating a self-reinforcing inhibitory loop.
• These findings highlight a novel molecular mechanism for WA's anti-cancer activity in HCC and suggest potential therapeutic strategies targeting the IGF2BP3/FOXO1/JAK2/STAT3 axis.